NewAmsterdam Pharma Management
Management criteria checks 2/4
NewAmsterdam Pharma's CEO is Michael Davidson, appointed in Aug 2020, has a tenure of 3.67 years. total yearly compensation is $5.81M, comprised of 9.8% salary and 90.2% bonuses, including company stock and options. directly owns 0.91% of the company’s shares, worth $16.11M. The average tenure of the management team and the board of directors is 2.3 years and 1.4 years respectively.
Key information
Michael Davidson
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 9.8% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.3yrs |
| Board average tenure | 1.4yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$569k | -US$177m |
Compensation vs Market: Michael's total compensation ($USD5.81M) is about average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
CEO
Michael Davidson (67 yo)
3.7yrs
Tenure
US$5,805,558
Compensation
Dr. Michael Harvey Davidson, M.D., FACC., FNLA, serves as Director at Nanophoria S.R.L. since January 2024. Dr. Davidson is a Co-Founder and Chief Scientific Officer of TROFI NUTRITIONALS, INC. Dr. Harvey...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 3.7yrs | US$5.81m | 0.91% $ 16.1m | |
| Founder | 5.3yrs | US$2.98m | 0.26% $ 4.6m | |
| Chief Financial Officer | less than a year | US$3.55m | no data | |
| Chief Business Officer | no data | US$45.63k | no data | |
| Chief Operating Officer | 3.1yrs | no data | 0% $ 0 | |
| Chief Legal Officer & Secretary | 1.4yrs | no data | no data | |
| Chief Development Officer | 1.7yrs | no data | 0% $ 0 | |
| VP & Head of Chemistry Manufacturing and Controls (CMC) | 3yrs | no data | no data | |
| VP & Head of Regulatory Affairs | 3.1yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: NAMS's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 1.4yrs | US$5.81m | 0.91% $ 16.1m | |
| Founder | 1.4yrs | US$2.98m | 0.26% $ 4.6m | |
| Non-Executive Director | 1.4yrs | US$339.05k | 0.028% $ 495.8k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Chairman of Board of Directors | less than a year | no data | no data | |
| Independent Director | 1.2yrs | US$138.83k | 0% $ 0 | |
| Board Observers | no data | no data | no data | |
| Board Observer | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Board Observer | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
1.4yrs
Average Tenure
67yo
Average Age
Experienced Board: NAMS's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.